Clinical Trial Update: An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 4]

View source ↗

Summary

This clinical trial update reports the results from an expanded access program of Tarceva (erlotinib) in participants with advanced non-small cell lung cancer (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Small Cell Lung Cancer | Phase 4 | Status: COMPLETED | Results posted: 2016-10-04